epilepsy

Truist Securities initiated coverage on Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), citing it as a CNS-focused biotech with high-value epilepsy assets. The company plans to advance its lead drug bexicaserin (LP352), into the Phase 3 program later this year. The FDA has granted Breakthrough...

Belgian-based UCB SA (OTC: UCBJF) has agreed to buy Zogenix Inc (NASDAQ: ZGNX), a U.S. maker of drugs to treat seizures and rare diseases, for $1.9 billion, expanding its portfolio to treat epilepsy. Investors will get $26 in cash for every Zogenix share, plus a potential...

Taysha Gene Therapies Inc (NASDAQ: TSHA) announced a late-breaking abstract and poster presentation on preclinical data for TSHA-105 for SLC13A5-related epilepsy. Data were shared at the American Epilepsy Society Annual Meeting. In knockout mouse models of SLC13A5 deficiency,...

Stoke Therapeutics Inc (NASDAQ: STOK) announced highlights from five presentations related to the ongoing clinical development of STK-001 being made at the American Epilepsy Society 2021 Annual Meeting. STK-001 is under development to target the underlying cause of Dravet syndrome,...

Xenon Pharmaceuticals Inc (NASDAQ: XENE) announced additional positive data from new sub-analyses of Phase 2b X-TOLE trial of XEN1101 in adult patients with focal epilepsy. The Data will be presented at the Annual Meeting of the American Epilepsy Society. Additional primary and...

Xenon Pharmaceuticals Inc (NASDAQ: XENE) has reported topline results from the Phase 2b X-TOLE trial evaluating XEN1101 as an adjunctive treatment in adult patients with focal epilepsy. The trial met its primary efficacy endpoint with XEN1101, demonstrating a statistically...

The European Commission has granted Orphan Drug designation to Taysha Gene Therapies Inc's (NASDAQ: TSHA) TSHA-105, AAV9-based gene therapy for SLC13A5-related epilepsy. Related: Taysha Gene Secures $100M In Debt Financing For Support Pipeline Development SLC13A5...

Pfizer Inc (NYSE: PFE) and Flynn Pharma Ltd have been accused by the U.K.'s competition watchdog of illegally overcharging the National Health Service (NHS) for anti-epilepsy drugs. What Happened: The Competition and Markets Authority (CMA) said that the companies used...

Marinus Pharmaceuticals Inc (NASDAQ: MRNS) has submitted a marketing application to the FDA seeking approval for its lead product candidate, ganaxolone, to treat seizures associated with CDKL5 deficiency disorder (CDD). An application filing notification letter from the FDA is...

OPKO Health Inc (NASDAQ: OPK) has entered into an exclusive worldwide agreement with privately-held CAMP4 Therapeutics Corporation (CAMP4) to develop, manufacture, and commercialize therapeutics utilizing the AntagoNAT technology. AntagoNATs are oligonucleotide compounds...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) presents sleep data from an open-label Phase 2 trial evaluating Zygel for developmental & epileptic encephalopathies (DEE) and autism spectrum disorder (ASD). Results were presented at the Associated Professional Sleep Societies SLEEP...

Zogenix Inc (NASDAQ: ZGNX) has announced new data showing the positive impact of treatment with Fintepla (fenfluramine) on everyday executive function for children and young adults with Lennox-Gastaut syndrome (LGS), a rare and severe kind of childhood epilepsy characterized by...

Cannabinoid-based drug maker GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) CEO Justin Gover told CNBC's Jim Cramer the company's approval to market Epidiolex across Europe is a "historic milestone" for the field of cannabinoid science. European Approval Epidiolex is the only CBD-...

Zogenix, Inc. (NASDAQ: ZGNX) peaked nearly 30 percent in Thursday's pre-market session after management released positive top-line results from its second pivotal Phase 3 study of ZX008 in Dravet Syndrome. The trial met primary and secondary endpoints and demonstrated statistical significance...